DiaMedica reports 2021 results: $45M cash, Phase 2/3 stroke trial underway

DiaMedica Therapeutics Inc.

Cash, cash equivalents and marketable securities $45.1M as of Dec 31, 2021; runway into 2024.
R&D expenses $8.8M for 2021 vs $8.2M prior year; net cash used in operations $12.3M.
Pivotal Phase 2/3 ReMEDy2 trial for DM199 in acute ischemic stroke dosing patients; interim analysis planned after ~140 patients.
Appointed Kirsten Gruis as CMO and Dom Cundari as CCO; last patient dosed in Phase 2 CKD REDUX trial.
No revenue reported; net loss for 2021 not explicitly given but reflected in increased cash used.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.